DeNovaMed

DeNovaMed is a Canadian biotechnology company dedicated to the discovery and development of a new class of antibiotics to address the global threat of multi-drug resistant (MDR) bacteria. The company utilizes a proprietary structure-based drug design platform to target the FabI enzyme, an essential component of the bacterial fatty acid synthesis pathway. Their lead programs focus on treating life-threatening infections caused by pathogens such as Methicillin-resistant Staphylococcus aureus (MRSA) and various Gram-negative bacteria. By developing inhibitors with a novel mechanism of action, DeNovaMed aims to overcome existing resistance mechanisms and provide effective treatments for hospital-acquired infections. The company's research originated from Dalhousie University and has received support from various Canadian innovation funds.